Page 52 - 2019_07 resto del Mondo-web

F. Khawaja et al.
57. Whimbey E, Couch RB, Englund JA, et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis. 1995;21(2):376-379.
58. Torres HA, Aguilera EA, Mattiuzzi GN, et al. Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia. Haematologica. 2007;92(9):1216- 1223.
59. Sheshadri A, Shah D, Kmeid J, et al. Pulmonary function decline after respiratory viral infection predicts mortality after hematopoietic stem cell transplantation. Am J Resp Crit Care Med 2017;195:A2706.
60. Erard V, Chien JW, Kim HW, et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis. 2006;193(12):1619-1625.
61. Fisher CE, Preiksaitis CM, Lease ED, et al. Symptomatic respiratory virus infection and chronic lung allograft dysfunction. Clin Infect Dis. 2016;62(3):313-319.
62. Abdallah A, Rowland KE, Schepetiuk SK, To LB, Bardy P. An outbreak of respiratory syn- cytial virus infection in a bone marrow transplant unit: effect on engraftment and outcome of pneumonia without specific antiviral treatment. Bone Marrow Transplant. 2003;32(2):195-203.
63. Chien JW, Martin PJ, Gooley TA, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell trans- plantation. Am J Respir Crit Care Med. 2003;168(2):208-214.
64. Abedin S, Yanik GA, Braun T, et al. Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus- host disease of the lung. Biol Blood Marrow Transplant. 2015;21(6):1127-1131.
65. Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med. 2004;170(2):181-187.
66. Versluys AB, Rossen JW, van Ewijk B, Schuurman R, Bierings MB, Boelens JJ. Strong association between respiratory viral infection early after hematopoietic stem cell transplantation and the development of life- threatening acute and chronic alloimmune lung syndromes. Biol Blood Marrow Transplant. 2010;16(6):782-791.
67. Yue C, Kang Z, Ai K, et al. Virus infection facilitates the development of severe pneu- monia in transplant patients with hemato- logic malignancies. Oncotarget. 2016;7(33): 53930-53940.
68. Ebbert JO, Limper AH. Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome. Respiration. 2005;72(3):263-269.
69. Peck AJ, Corey L, Boeckh M. Pretransplantation respiratory syncytial virus infection: impact of a strategy to delay transplantation. Clin Infect Dis. 2004;39(5):673-680.
70. Campbell AP, Guthrie KA, Englund JA, et al. Clinical outcomes associated with respirato- ry virus detection before allogeneic hematopoietic stem cell transplant. Clin Infect Dis. 2015;61(2):192-202.
71. Boeckh M, Englund J, Li Y, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncy- tial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2007;44(2):245-249.
72. Field K, Slavin MA, Seymour JF. Severe res- piratory syncytial virus pneumonia compli- cating fludarabine and cyclophosphamide
treatment of chronic lymphocytic leukemia.
Eur J Haematol. 2002;69(1):54-57.
73. Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant.
2000;25(7):751-755.
74. McColl MD, Corser RB, Bremner J, Chopra
R. Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin. Bone Marrow Transplant. 1998;21(4):423-425.
75. McCoy D, Wong E, Kuyumjian AG, Wynd MA, Sebti R, Munk GB. Treatment of respi- ratory syncytial virus infection in adult patients with hematologic malignancies based on an institution-specific guideline. Transpl Infect Dis. 2011;13(2):117-121.
76. Sparrelid E, Ljungman P, Ekelof-Andstrom E, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant. 1997;19(9):905-908.
77. Win N, Mitchell D, Pugh S, Russell NH. Successful therapy with ribavirin of late onset respiratory syncytial virus pneumoni- tis complicating allogeneic bone transplanta- tion. Clin Lab Haematol. 1992;14(1):29-32.
78. Chemaly RF, Torres HA, Munsell MF, et al. An adaptive randomized trial of an intermit- tent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syn- cytial virus infection. J Infect Dis. 2012;206(9):1367-1371.
79. Marcelin JR, Wilson JW, Razonable RR; Mayo Clinic Hematology/Oncology. Transplant Infectious Diseases Services. Oral ribavirin therapy for respiratory syncy- tial virus infections in moderately to severe- ly immunocompromised patients. Transpl Infect Dis. 2014;16(2):242-250.
80. Schleuning M, Buxbaum-Conradi H, Jager G, Kolb HJ. Intravenous ribavirin for eradi- cation of respiratory syncytial virus (RSV) and adenovirus isolates from the respiratory and/or gastrointestinal tract in recipients of allogeneic hematopoietic stem cell trans- plants. Hematol J. 2004;5(2):135-144.
81. Casey J, Morris K, Narayana M, Nakagaki M, Kennedy GA. Oral ribavirin for treat- ment of respiratory syncitial virus and parainfluenza 3 virus infections post allo- geneic haematopoietic stem cell transplanta- tion. Bone Marrow Transplant. 2013;48(12):1558-1561.
82. Gueller S, Duenzinger U, Wolf T, et al. Successful systemic high-dose ribavirin treatment of respiratory syncytial virus- induced infections occurring pre-engraft- ment in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2013;15(4):435-440.
83. Lewinsohn DM, Bowden RA, Mattson D, Crawford SW. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplanta- tion. Antimicrob Agents Chemother. 1996;40(11):2555-2557.
84. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoi- etic stem cell transplantation. Blood. 2011;117(10):2755-2763.
85. Chemaly RF, Aitken SL, Wolfe CR, Jain R, Boeckh MJ. Aerosolized ribavirin: the most expensive drug for pneumonia. Transpl Infect Dis. 2016;18(4):634-636.
86. Chakrabarti S, Collingham KE, Holder K, Fegan CD, Osman H, Milligan DW. Pre- emptive oral ribavirin therapy of paramyx-
ovirus infections after haematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant. 2001;28(8):759- 763.
87. Gorcea CM, Tholouli E, Turner A, et al. Effective use of oral ribavirin for respiratory syncytial viral infections in allogeneic haematopoietic stem cell transplant recipi- ents. J Hosp Infect. 2017;95(2):214-217.
88. Mori T, Nakamura Y, Kato J, et al. Oral rib- avirin therapy for lower respiratory tract infection of respiratory syncytial virus com- plicating bronchiolitis obliterans after allo- geneic hematopoietic stem cell transplanta- tion. Int J Hematol. 2011;93(1):132-134.
89. Gupta SK, Kantesaria B, Glue P. Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment. Drug Discov Ther. 2013;7(4):158-163.
90. Foolad F, Aitken SL, Shigle TL, et al. Oral versus aerosolized ribavirin for the treat- ment of respiratory syncytial virus infec- tions in hematopoietic cell transplantation recipients. Clin Infect Dis. 2018 Sep 8. [Epub ahead of print]
91. Chaves J, Huen A, Bueso-Ramos C, Safdar A, Vadhan-Raj S. Aerosolized ribavirin- induced reversible hepatotoxicity in a hematopoietic stem cell transplant recipient with Hodgkin lymphoma. Clin Infect Dis. 2006;42(8):e72-75.
92. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal amino- transferase levels. Hepatology. 1997;26(3 Suppl 1):133S-136S.
93. Falsey AR, Koval C, DeVincenzo JP, Walsh EE. Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immuno- compromised persons. Transpl Infect Dis. 2017;19(2).
94. Markovic SN, Adlakha A, Smith TF, Walker RC. Respiratory syncytial virus pneumoni- tis-induced diffuse alveolar damage in an autologous bone marrow transplant recipi- ent. Mayo Clin Proc. 1998;73(2):153-156.
95. de Fontbrune FS, Robin M, Porcher R, et al. Palivizumab treatment of respiratory syncy- tial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2007;45(8):1019-1024.
96. Tsitsikas DA, Oakervee H, Cavenagh JD, Gribben J, Agrawal SG, Mattes FM. Treatment of respiratory syncytial virus infection in haemopoietic stem cell trans- plant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience. Br J Haematol. 2009;146(5):574-576.
97. Permpalung N, Mahoney MV, McCoy C, et al. Clinical characteristics and treatment out- comes among respiratory syncytial virus (RSV)-infected hematologic malignancy and hematopoietic stem cell transplant recipients receiving palivizumab. Leuk Lymphoma. 2019;60(1):85-91.
98. German P, Xin Y, Chien JW, et al. Phase 1 first-in-human, single- and multiple-ascend- ing dose, and food effect studies to assess the safety, tolerability, and pharmacokinet- ics of presatovir for the treatment of respira- tory syncytial virus infection. J Clin Pharmacol. 2018 Apr 17. [Epub ahead of print]
99. Marty FMC, Roy F, Bergeron A, et al. A phase 2b, randomized, double-blind, èlace- bo-controlled trial of presatovir (GS-5806) for the treatment of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in hematopoietic-cell transplantation
1330
haematologica | 2019; 104(7)